IL17A and inflammatory bowel disease: In addition, treatment with IL-17 inhibitors in psoriasis and PsA can induce the development or aggravation of IBD in susceptible patients, although whether it is the development of IBD observed in predisposing patients or inhibiting IL-17 that causes the de novo development of IBD needs to be further determined in future studies [140].